The DOI matches its Crossref record.
Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation
Abstract
Dextromethorphan hydrobromide, 25 mg po, was given to 268 unrelated Swiss subjects to study urinary drug and metabolite profiles. Rates of O-demethylation yielding the main metabolite dextrorphan were expressed by the urinary dextromethorphan/dextrorphan metabolic ratio. We found a bimodal distribution of this parameter in our population study, which indicates that there are two phenotypes for dextromethorphan O-demethylation. The antimode at a metabolic ratio of 0.3 separated the poor metabolizer (PM; n = 23; prevalence of 9%) from extensive metabolizer (EM) phenotypes. Urinary output of dextrorphan was less than 6% of the dose in all PMs and was 50% in the 245 EMs. Pedigree analysis of 14 family studies revealed an autosomal-recessive transmission of deficient dextromethorphan O-demethylation. In these families, 37 heterozygous genotypes could be identified; however, through use of the urinary drug and metabolite analysis it was not possible to identify the heterozygous genotypes within the EM phenotype group. Co-segregation of dextromethorphan O-demethylation with debrisoquin 4-hydroxylation was also studied. Complete concordance of the two phenotypic assignments was obtained, with a Spearman rank correlation coefficient of rs = 0.78 (n = 62; P less than 0.0001) for dextromethorphan and debrisoquin metabolic ratios. Presumably the two drug oxidation polymorphisms are under the same genetic control. Thus the innocuousness and ubiquitous availability of dextromethorphan render it attractive for worldwide pharmacogenetic investigations in man.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype
Gaedigk, A., Simon, S., Pearce, R., Bradford, L., Kennedy, M., & Leeder, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100406 · Cited by 779
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Streetman, D. S., Bertino, J. S., & Nafziger, A. N. (2000) · Pharmacogenetics · doi:10.1097/00008571-200004000-00001 · Cited by 425
Effect of St John's Wort on Drug Metabolism by Induction of Cytochrome P450 3A4 Enzyme
Markowitz, J. S. (2003) · JAMA · doi:10.1001/jama.290.11.1500 · Cited by 403
Non‐linear pharmacokinetics of MDMA (‘ecstasy’) in humans
De La Torre, R., Farré, M., Ortuño, J., Mas, M., Brenneisen, R., Roset, P. N., Segura, J., & Camí, J. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00121.x · Cited by 401
The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects
Eichelbaum, M., & Gross, A. S. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90025-w · Cited by 368
Mas, M., Farré, M., de la Torre, R., Roset, P. N., Segura, J. O., & Camí, J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34877-3 · Cited by 362
Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
Alv�n, G., Bechtel, P., Iselius, L., & Gundert-Remy, U. (1990) · European Journal of Clinical Pharmacology · doi:10.1007/bf00316090 · Cited by 361
Applications of CYP450 Testing in the Clinical Setting
Samer, C. F., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0028-5 · Cited by 354
Wormhoudt, L. W., Commandeur, J. N. M., & Vermeulen, N. P. E. (1999) · Critical Reviews in Toxicology · doi:10.1080/10408449991349186 · Cited by 302
Clinical significance of the sparteine/debrisoquine oxidation polymorphism
Br�sen, K., & Gram, L. F. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00637732 · Cited by 282
Camí, J., Farré, M., Mas, M., Roset, P. N., Poudevida, S., Mas, A., San, L., & de la Torre, R. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200008000-00010 · Cited by 234
Vorrink, S. U., Ullah, S., Schmidt, S., Nandania, J., Velagapudi, V., Beck, O., Ingelman‐Sundberg, M., & Lauschke, V. M. (2017) · The FASEB Journal · doi:10.1096/fj.201601375r · Cited by 172
Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans
Vermeir, M., Naessens, I., Remmerie, B., Mannens, G., Hendrickx, J., Sterkens, P., Talluri, K., Boom, S., Eerdekens, M., van Osselaer, N., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018275 · Cited by 158
Carbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4769-4 · Cited by 133
Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan
Nguyen, L., Robson, M. J., Healy, J. R., Scandinaro, A. L., & Matsumoto, R. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089985 · Cited by 99
Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice
Nguyen, L., & Matsumoto, R. R. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.03.024 · Cited by 51
Ito, T., Kato, M., Chiba, K., Okazaki, O., & Sugiyama, Y. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.25.243 · Cited by 23
Metadata
- Authors
- Schmid, B., Bircher, J., Preisig, R., & Küpfer, A.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1985-12
- Volume
- 38
- Issue
- 6
- Pages
- 618-624
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1971080708
- Cited by
- 383
- References
- 0
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.